Durect Corp.
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 30.1m | 14.0m | 19.3m | 8.5m | 8.0m | 8.6m | 23.2m |
| % growth | 2 % | (54 %) | 38 % | (56 %) | (7 %) | 7 % | 170 % |
| EBITDA | (12.1m) | (34.1m) | (32.9m) | (34.7m) | - | - | - |
| % EBITDA margin | (40 %) | (244 %) | (171 %) | (406 %) | - | - | - |
| Profit | (<1m) | (36.3m) | (35.3m) | (27.6m) | (27.0m) | (41.4m) | (37.5m) |
| % profit margin | (2 %) | (259 %) | (183 %) | (323 %) | (339 %) | (483 %) | (162 %) |
| EV / revenue | 14.0x | 16.1x | 4.1x | 2.1x | 5.8x | 5.4x | 2.0x |
| EV / EBITDA | -34.8x | -6.6x | -2.4x | -0.5x | - | - | - |
| R&D budget | 27.7m | 31.8m | 36.9m | 29.4m | - | - | - |
| R&D % of revenue | 92 % | 228 % | 191 % | 343 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $5.6m | Series A | |
$9.4m | Series A | ||
$20.1m | Series B | ||
$25.0m | Series C | ||
| N/A | N/A | IPO | |
$20.0m | Post IPO Equity | ||
| N/A | $42.5m | Post IPO Equity | |
* | N/A | $15.0m | Post IPO Equity |
| Total Funding | €54.7m | ||
Related Content
Recent News about Durect Corp.
EditDURECT Corporation is a biopharmaceutical company focused on developing innovative therapies for acute organ injury and chronic liver diseases. The company leverages its epigenetic regulator program and proprietary drug delivery technologies to create novel treatments for diseases with limited current options. DURECT's pipeline includes DUR-928, the first endogenous epigenetic regulator clinically tested for treating acute organ injury and chronic liver diseases, and other investigational drugs like a non-opioid analgesic for post-surgical pain relief and a tamper-resistant ADHD medication. The company operates in the healthcare and pharmaceutical markets, primarily serving patients with unmet medical needs. DURECT generates revenue through the development and commercialization of its drug candidates, as well as through partnerships and licensing agreements.
Keywords: biopharmaceutical, epigenetic regulator, drug delivery, acute organ injury, chronic liver diseases, DUR-928, non-opioid analgesic, ADHD medication, proprietary technologies, healthcare.
Tech stack
Investments by Durect Corp.
Edit